François M. Legault

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Ecopia is finding novel anticancer therapies from soil-dwelling micro organisms that are as of this day one of the most prolific sources of these drugs. Their current focus is ECO-4601, a new small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain. Just like well-known chemotherapies such as doxorubicin and daunorubicin, ECO-4601 comes from microorganisms that live in common soil. ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology

Picchio Pharma, Inc. engages in acquiring, developing, and commercializing new therapeutic products and technologies. The company was founded in 2001 and is headquartered in Laval, Canada.

Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies.

Adaltis, Inc. is an international in-vitro diagnostic company. The company develops, manufactures and markets in-vitro diagnostic systems and reagent products to detect viral infections, diagnose immune system diseases and measure human hormone responses. Adaltis was founded on June 12, 1987 and is headquartered in Montreal, Canada.

ViroChem Pharma, Inc. provides antiviral drug research and development services. The company provides R&D services on HIV/AIDS and hepatitis C. It was founded on April 8, 2004 and is headquartered in Laval, Canada.

Thallion Pharmaceuticals, Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its products are Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections and TLN-4601, a proprietary first in class small molecule with potential efficacy in multiple oncology indications. The company was founded in January 1998 and is headquartered in Dorval, Canada.

CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada.

Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland.